Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

CKD is currently developing CKD-702, a bispecific antibody directed against epidermal growth factor receptor (EGFR) and the tyrosine-kinase mesenchymal-epithelial transition (MET) factor receptor ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

EpiBiologics, a leader in tissue-selective extracellular protein degradation, today presented the first preclinical data on its EpiTAC bispecific antibody degrader of c-Met, a potential first-in-class ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...

Newer-generation Bruton's tyrosine kinase (BTK) inhibitors have found a place in the management of follicular lymphoma, a ...

AVEO Oncology, an LG Chem company ("AVEO"), a biopharmaceutical company committed to providing differentiated solutions to ...

The c-Met-directed antibody-drug conjugate telisotuzumab ... The c-Met protein is a receptor tyrosine kinase that mediates cell proliferation, survival, and angiogenesis, and can be dysregulated ...